Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

Considering lifestyle and environment to maximize the economic value of R&D

Posted on November 10th, 2017 by in Pharma R&D

With an interest in systems approaches, I am always on the look-out for interesting papers in this area. A recent paper in Drug Discovery Today caught my eye for several reasons (1). The first was the extent of the problem with non-alcoholic liver disease. (more…)

Pharma Companies United By a Need for Common Data Models

Posted on October 18th, 2017 by in Pharma R&D

There is nothing that pharmaceutical companies guard more fiercely than their intellectual property. Devising and patenting the next big wonder drug is every company’s dream (more…)

Big Data and Proactive Pharmacovigilance

Posted on September 20th, 2017 by in Pharmacovigilance

Traditionally thought of as a post-market process, pharmacovigilance is how pharmaceutical companies monitor and address any safety issues that arise once a drug becomes available commercially. However, some companies are now thinking ahead about these potential safety concerns with what is known as “proactive PV”. (more…)

Taking a Balanced Approach to Monitoring Literature

Posted on September 11th, 2017 by in Pharmacovigilance

In a time when the focus on pharmacovigilance is greater than ever before, literature monitoring presents pharmaceutical companies with significant challenges. Pharmacovigilance groups are looking for ways to efficiently and cost-effectively manage an increasing workload while remaining compliant with regulatory best practices. (more…)

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 7